Primary liver tumors - Diagnostic, predictive and prognostic aspects - Prof. Fabio Piscaglia

Areas of research

Prof. Piscaglia's research group combines expertise in the fields of medicine and cellular and molecular biology to study hepatocarcinoma by analyzing its mechanisms of development, response, and resistance to treatment. Research activities are set in a purely translational perspective and focused on the characterization of subgroups of patients affected by this disease, to identify biomarkers and personalize clinical management, including the choice of treatments, as much as possible. To this end, the group collaborates closely with the liver disease surgery and liver transplantation group. The main strands of research include transcriptomic and immunohistochemical characterization of HCC subgroups identified on the basis of clinical characteristics of patients; immunophenotypic and transcriptomic characterization of circulating cell populations in patients with HCC; and study of response to treatments both in patients and in hepatocarcinoma cell lines, evaluating the molecular modulation induced by the treatments themselves and validating their validity on biological material obtained from patients.

Research Projects at CRBA

Liquid biopsy for personalizing drug therapy of hepatocarcinoma.
Molecular characterization of hepatocarcinoma aimed at personalizing treatments.

PUBLICATIONS

Leggi dettagli

1. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1. PMID: 29433850. IF: 202.7

2. Gramantieri L, Gnudi F, Vasuri F, Mandrioli D, Fornari F, Tovoli F, Suzzi F, Vornoli A, D'Errico A, Piscaglia F, Giovannini C. Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area. Nutrients. 2022 Apr 15;14(8):1652. doi: 10.3390/nu14081652. PMID: 35458213; PMCID: PMC9024438. IF: 5.7

3. Gramantieri L, Giovannini C, Suzzi F, Leoni I, Fornari F. Hepatic Cancer Stem Cells: Molecular Mechanisms, Therapeutic Implications, and Circulating Biomarkers. Cancers (Basel). 2021 Sep 10;13(18):4550. doi: 10.3390/cancers13184550. PMID: 34572776; PMC8472624. IF: 6.6

4. Gramantieri L, Giovannini C, Piscaglia F, Fornari F. MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021 May 12; 8: 369-385. doi: 10.2147/JHC.S268292. PMID: 34012928; PMCID: PMC8126872. IF: 4.9

5. D'Avola D, Granito A, Torre-Aláez M, Piscaglia F. The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. J Hepatol. 2022 May;76(5):1185-1198. doi: 10.1016/j.jhep.2021.11.013. Epub 2021 Nov 15. PMID: 34793869. IF: 25

6. Gramantieri L, Pollutri D, Gagliardi M, Giovannini C, Quarta S, Ferracin M, Casadei-Gardini A, Callegari E, De Carolis S, Marinelli S, Benevento F, Vasuri F, Ravaioli M, Cescon M, Piscaglia F, Negrini M, Bolondi L, Fornari F. MiR-30e-3p Influences Tumor Phenotype through MDM2/TP53 Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma. Cancer Res. 2020 Apr 15;80(8):1720-1734. doi: 10.1158/0008-5472.CAN-19-0472. Epub 2020 Feb 3. PMID:32015093. IF: 13.3

7. Giovannini C, Salzano AM, Baglioni M, Vitale M, Scaloni A, Zambrano N, Giannone FA, Vasuri F, D'Errico A, Svegliati Baroni G, Bolondi L, Gramantieri L. Brivanib in combination with Notch3 silencing shows potent activity in tumour models. Br J Cancer. 2019 Mar;120(6):601-611. doi: 10.1038/s41416-018-0375-4. Epub 2019 Feb 15. PMID: 30765875; PMCID: PMC6461893. IF: 7.6

8. Gramantieri L, Baglioni M, Fornari F, Laginestra MA, Ferracin M, Indio V, Ravaioli M, Cescon M, De Pace V, Leoni S, Coadă CA, Negrini M, Bolondi L, Giovannini C. LncRNAs as novel players in hepatocellular carcinoma recurrence. Oncotarget. 2018 Oct 12;9(80):35085-35099. doi: 10.18632/oncotarget.26202. PMID: 30416681; PMCID: PMC6205555. IF: 3.3

9. Piscaglia F, Granito A, Bolondi L. DAAs for HCV and risk of hepatocellular carcinoma: current standpoint. Lancet Gastroenterol Hepatol. 2018 Nov;3(11):736-738. doi: 10.1016/S2468-1253(18)30238-3. PMID: 30353852. IF: 45
10. Peter R Galle, Alejandro Forner, Josep M Llovet, Vincenzo Mazzaferro, Fabio Piscaglia, Jean-Luc Raoul, Peter Schirmacher, Valérie Vilgrain. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5. IF: 25

A more extensive list of the most relevant publications related to laboratory activities can be freely viewed here:
https://pubmed.ncbi.nlm.nih[…]gramantieri+l&sort=date

TEAM MANAGER

Fabio Piscaglia

Write an e-mail

Team

Primary liver tumors - Diagnostic, predictive and prognostic aspects - Prof. Fabio Piscaglia

Areas of research

Research Projects at CRBA

PUBLICATIONS

TEAM MANAGER

Fabio Piscaglia

Team

Catia Giovannini

Laura Gramantieri

Fabrizia Suzzi

Annapaola Montagner